Oseltamivir Dosing Guidelines for Renal Impairment

Introduction to Renal Dose Adjustment

• The American College of Physicians and other guideline societies recommend that for patients with creatinine clearance (CrCl) 10-30 mL/min, the treatment dose of oseltamivir should be reduced to 75 mg once daily for 5 days and the prophylaxis dose to 75 mg every other day; for patients with CrCl <10 mL/min or on hemodialysis, 30 mg per hemodialysis cycle for treatment and 30 mg every alternate hemodialysis cycle for prophylaxis should be used 1, 2

Critical Threshold for Dose Adjustment

• The key threshold for oseltamivir dose reduction is CrCl <30 mL/min, not 46 mL/min or other values, as recommended by the Centers for Disease Control and Prevention (CDC) and supported by evidence from MMWR Recommendations and Reports 1, 3, 4
• No dose adjustment is required based on age alone, even in patients >65 years, according to the CDC and MMWR Recommendations and Reports 3, 4

Standard Dosing (CrCl ≥30 mL/min)

• The standard treatment regimen is 75 mg orally twice daily for 5 days, as recommended by the Infectious Diseases Society of America (IDSA) and supported by Praxis Medical Insights 1
• The standard prophylaxis regimen is 75 mg orally once daily for at least 10 days following exposure or up to 6 weeks during community outbreak, as recommended by the IDSA and supported by Praxis Medical Insights 1

Moderate Renal Impairment (CrCl 10-30 mL/min)

• The treatment dose should be reduced to 75 mg once daily for 5 days, as recommended by the National Kidney Foundation and supported by MMWR Recommendations and Reports 1, 3, 4
• The prophylaxis dose should be reduced to 75 mg every other day, as recommended by the National Kidney Foundation and supported by MMWR Recommendations and Reports 1, 3, 4

Severe Renal Impairment (CrCl <10 mL/min)

• For patients on hemodialysis, the treatment dose should be 30 mg administered after each hemodialysis session, as recommended by the CDC and supported by Praxis Medical Insights 1, 2
• For patients on hemodialysis, the prophylaxis dose should be 30 mg after every alternate hemodialysis session, as recommended by the CDC and supported by Praxis Medical Insights 1, 2

Alternative: Zanamivir for Renal Impairment

• Zanamivir (inhaled) requires no dose adjustment in any degree of renal impairment, including end-stage renal disease, making it a suitable option for patients with severe renal dysfunction, as recommended by the American Thoracic Society and supported by MMWR Recommendations and Reports 2, 3, 4
• Zanamivir dosing is 10 mg (two inhalations) twice daily for treatment or once daily for prophylaxis, regardless of renal function, as recommended by the American Thoracic Society and supported by Praxis Medical Insights 2

Oseltamivir Dosing in Severe Renal Impairment (CrCl 10–30 mL/min)

Treatment Dosing

• The Advisory Committee on Immunization Practices (ACIP) recommends a 75 mg oral dose once daily for 5 days in patients with creatinine clearance 10–30 mL/min (severe renal impairment) [5][6]7.
• This regimen is classified as a strong recommendation in the ACIP guidance.

Prophylaxis Dosing

• For post‑exposure prophylaxis, ACIP advises 75 mg orally every other day for 10 days (total of 5 doses) in the same renal function category [5][6]7.
• An alternative 30 mg once daily for 10 days is also acceptable, though less commonly used [5][6]7.

Dose‑Adjustment Rationale

• The dose‑reduction threshold is creatinine clearance <30 mL/min, independent of age or other factors [5][6][7][8].
• Oseltamivir carboxylate, the active metabolite, is eliminated >99 % by renal excretion; serum concentrations rise inversely with declining renal function [5][6][7][8].
• Without adjustment, patients with CrCl 10–30 mL/min experience 2–3‑fold higher drug exposure than those with normal renal function, increasing toxicity risk [5][6][7][8].

Alternative Antiviral (Zanamivir)

• The CDC/ACIP notes that zanamivir does not require dose adjustment for any level of renal impairment, including severe impairment and end‑stage renal disease [5][6][7][8].
• Recommended dosing: 10 mg (two inhalations) twice daily for treatment or once daily for prophylaxis, regardless of renal function [5][6][7][8].
• Rationale: inhaled administration results in minimal systemic absorption and negligible renal clearance [5][6][7][8].
• Caution: zanamivir is contraindicated in patients with underlying airway disease (e.g., asthma, COPD) due to bronchospasm risk.

Monitoring & Safety

• Renal function monitoring is advised for all patients with any degree of renal insufficiency receiving oseltamivir [5][6]7.
• If toxicity (e.g., neuropsychiatric symptoms, severe gastrointestinal distress) develops, dose reduction or discontinuation should be considered [5][6]7.

Summary Table

All dosing recommendations are based on ACIP/CDC MMWR guidance (2000‑2004) [5][6][7][8].

Renal Dose Adjustments for Oseltamivir and Alternative Therapy

Age‑Based Dosing

• The CDC (MMWR Recommendations and Reports) states that no oseltamivir dose adjustment is required based solely on age, even for patients ≥ 65 years with normal renal function. 9

Moderate Renal Impairment (Creatinine Clearance 10–30 mL/min)

• For patients with CrCl 10–30 mL/min, the CDC recommends reducing the oseltamivir treatment regimen to 75 mg orally once daily for 5 days (instead of the standard twice‑daily schedule). 9
• For the same renal range, the CDC advises a prophylaxis regimen of 75 mg orally every other day for 10 days (total of 5 doses). 9

Zanamivir as an Alternative in Renal Impairment

• The CDC notes that inhaled zanamivir does not require any dose adjustment for any degree of renal impairment, including end‑stage renal disease, making it a suitable alternative for patients with severe renal dysfunction. 9
• Recommended zanamivir dosing, irrespective of renal function, is 10 mg (two inhalations) twice daily for treatment or once daily for prophylaxis. 9
• Zanamivir is contraindicated in patients with underlying airway disease (e.g., asthma, COPD) because of the risk of bronchospasm. 9